Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05711394 · ClinicalTrials.gov registry record · Phase 3

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

A Phase 3 study of Episodic Migraine, sponsored by AbbVie.

Recruiting
Registry status
Phase 3
Development phase
450
Enrollment target
20
Study locations

NCT05711394: Recruiting Phase 3 study of Episodic Migraine, sponsored by AbbVie.

NCT05711394 is a Phase 3 study of Episodic Migraine that is actively recruiting participants, run by AbbVie. The registered enrollment target is 450 participants, roughly in line with the 462-participant average among 13 other Episodic Migraine trials with a reported enrollment target. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05711394, a Phase 3 study of Episodic Migraine, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 3
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide. Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical a

Primary Outcome

A migraine day is defined as any calendar day on which a migraine occurs as per participant eDiary. Calendar days begin at midnight and last until 11:59 PM.

Conditions Studied

Episodic Migraine

Interventions

  • DRUG Atogepant
  • DRUG Placebo-Matching Atogepant

Study Locations (20)

California

  • Advanced Research Center /ID# 251381 - Anaheim
  • Alliance for Research Alliance for Wellness /ID# 248521 - Long Beach
  • Excell Research, Inc /ID# 247532 - Oceanside
  • Lumos Clinical Research Center /ID# 249731 - San Jose
  • Sunwise Clinical Research /ID# 248529 - Walnut Creek

Florida

  • Northwest Florida Clinical Research Group, LLC /ID# 251382 - Gulf Breeze
  • Advanced Research Institute of Miami /ID# 248539 - Homestead
  • My Preferred Research LLC /ID# 249720 - Miami
  • Asclepes Research Centers - Spring Hill /ID# 248525 - Spring Hill

Alabama

  • Rehabilitation & Neurological Services /ID# 248517 - Huntsville
  • The Center for Clinical Trials - Saraland /ID# 271604 - Saraland

Arkansas

  • Preferred Research Partners /ID# 249729 - Little Rock
  • Preferred Research Partners /ID# 270406 - Little Rock

Colorado

  • Advanced Neurosciences Research, LLC /ID# 247592 - Fort Collins

Georgia

  • Coastal Georgia Child Neurology /ID# 249733 - Brunswick

Indiana

  • Deaconess Clinic - Gateway Health Center /ID# 247589 - Newburgh

Kansas

  • College Park Family Care Center Overland Park /ID# 249734 - Overland Park

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2023-05-01
Est. Completion 2028-05
Phase Phase 3
AbbVie

526 total trials

What NCT05711394 shows while recruiting

NCT05711394 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 462-participant average among 13 other Episodic Migraine trials with a reported enrollment target.

The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Atogepant is the first listed.

NCT05711394 names 20 study sites across 11 states, led by California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT05711394 about?

NCT05711394 is a clinical study titled "A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine". A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved...

What is the current status of trial NCT05711394?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2023-05-01. Estimated completion is 2028-05.

What conditions does trial NCT05711394 study?

This clinical trial studies the following conditions: Episodic Migraine.

What interventions are being tested in trial NCT05711394?

The interventions under investigation include: Atogepant (DRUG), Placebo-Matching Atogepant (DRUG).

Who is sponsoring clinical trial NCT05711394?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05711394 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Episodic Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05711394's enrollment target sits among peer trials

450 9th of 13 higher than 5 of 13 other Episodic Migraine trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Episodic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00515060 · 450 participants

    Psychophysical Studies of Cancer Therapy Pain

  • NCT01257269 · 450 participants

    Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

  • NCT03047161 · 450 participants

    Electrophysiology of Fetal Arrhythmia

  • NCT03269630 · 450 participants

    New Orleans Pulmonary Hypertension Biobank

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05711394

Source: ClinicalTrials.gov NCT05711394, the US trial registry maintained by the National Library of Medicine. NCT05711394 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.